Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...

UT Dell Medical School study helps solve question of when to start blood thinners after a stroke in someone with AFib.

These five blue-chip dividend stocks have had a tough 2025 but are solid long-term buys for growth and income investors.

A direct-to-consumer program for its drugs could bring down higher U.S. drug prices while cutting out pharmacy benefit managers.

Bristol-Myers Squibb Co.’s chief medical officer is stepping down from his role after six years at the company, a surprise ...

The Swiss drugmaker discussed the option of selling drugs directly to patients with U.S. officials following Trump ...

Bristol Myers (BMY) delivered an impressive performance in the past month after being under pressure for quite some time. The ...

Pharma’s next big leap won’t come from the lab. It’ll come from outside the lab, where the rules of narrative, attention, and ...

Pfizer saw a staggering increase in call options trading, with investors snapping up 539,824 contracts, marking a 286% jump ...